From High-Throughput Screening to Scalable Production of Functional Proteins. Escherichia coli remains the premier host for recombinant protein production due to its rapid doubling time, high yield potential, and well-characterized genetic background. However, challenges such as strain-specific compatibility, the formation of insoluble inclusion bodies, and the high cost of downstream processing often hinder project success. CD Biosynsis provides professional E. coli Protein Expression and Purification Services, leveraging optimized high-throughput screening and advanced refolding strategies to deliver high-purity, bioactive proteins for diagnostics, structural biology, and therapeutic research.
Get a Technical QuoteWe offer a comprehensive "Gene-to-Protein" solution, encompassing everything from codon optimization to large-scale, endotoxin-free purification. Our platform is designed to meet the rigorous standards of industrial and clinical research.
| Service Tier | Technical Strategy | Best For | Standard Deliverables |
|---|---|---|---|
| Standard Expression | BL21(DE3) / Routine Induction | Soluble enzymes and routine proteins | Purified protein (>90%) + SDS-PAGE report |
| HTP Screening | Multi-strain & Multi-condition | Optimization of difficult-to-express targets | Optimal strain ID + Pilot expression data |
| Refolding Service | Inclusion Body Solubilization | Insoluble proteins / Eukaryotic domains | Refolded active protein + Bioactivity data |
| Diagnostic Grade | Multi-step Chromatography | Antigens & Antibodies for high-sensitivity assays | Endotoxin-free protein + Functional validation |
1. Design & Synthesis
2. Expression Optimization
3. Protein Harvesting
4. Validation & Delivery
Target evaluation, codon optimization, and selection of the most suitable fusion tags.
Formal project proposal and Mutual NDA signing.
Parallel testing of induction temperatures (16C to 37C), IPTG concentrations, and media formulations.
HTP screening for strain-condition pairing optimization.
Efficient cell lysis via optimized sonication or high-pressure homogenization.
Affinity chromatography (Ni-NTA/GST) followed by necessary inclusion body processing.
Purity verification via SDS-PAGE/HPLC and secondary purification (IEX/SEC).
Final QC report delivery and functional validation (e.g., ELISA).
To deliver superior service, our technical team continuously monitors and benchmarks our protocols against landmark research in the field. Please note that these studies represent established academic benchmarks and were not conducted by our company.
To address the "strain selection" bottleneck common in industrial production, academic research has established scalable high-throughput screening platforms. By utilizing Ligation-Independent Cloning (LIC) for rapid library construction and screening diverse E. coli hosts (e.g., BL21(DE3), Rosetta) in 96-well formats, it is possible to rapidly lock in the optimal strain and induction parameters (temperature, time, IPTG) to maximize recombinant yield.
(Reference: Morão LG et al., 2021)
When expressing eukaryotic proteins, misfolding often leads to insoluble inclusion bodies. Technical literature suggests that low-temperature induction (e.g., 16C) can slow translation rates to promote correct folding. Furthermore, adding chemical chaperones (e.g., glycerol, proline) helps maintain solubility. For proteins already in inclusion bodies, high-purity functional proteins can still be recovered through scientific refolding processes (e.g., removing denaturants while maintaining correct disulfide bond formation).
(Reference: Bhatwa A et al., 2021)
In the development of high-sensitivity serological assays, targeting critical protein domains (such as the C-terminal domain of the SARS-CoV-2 S1 subunit) rather than the full-length protein can be a highly effective strategy. By combining affinity chromatography with ion-exchange chromatography for secondary purification and strictly removing endotoxins, recombinant proteins can be obtained that demonstrate excellent antibody-capture capabilities in ELISA tests.
(Reference: Pambudi S et al., 2024)
To support large-scale production, research has proposed practical strategies for the regeneration of purification columns. By using specific low-pH or high-salt buffers to clean silica-based columns, it is possible to maintain purity and binding capacity across multiple cycles of reuse, significantly optimizing the costs of downstream purification for industrial-scale projects.
(Reference: Zhou Y et al., 2018)
1. What happens if my protein is expressed in inclusion bodies?
We offer solubility optimization (testing different tags/strains) and inclusion body refolding. Our refolding service screens for the optimal buffer (pH, redox pairs) to ensure the protein regains its native conformation.
2. Can you remove the fusion tag after purification?
Yes. We can design vectors with protease cleavage sites (e.g., TEV, Thrombin). After tag removal, we perform subtractive purification to deliver the tag-free target protein.
3. Do you provide endotoxin removal for cell-based assays?
Yes. We offer specialized endotoxin removal and LAL testing to ensure levels meet the requirements for sensitive biological applications (typically below 0.1 EU/microgram).
4. How do you handle proteins that are toxic to E. coli?
We use tightly regulated expression systems and low-temperature induction to prevent premature expression and ensure host viability during growth.
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.